Prescient Diagnostics: Implications for Product Development and Reimbursement

Major changes in the diagnostics industry are underway with an increased push to self-testing, digital diagnostic products, AI based multi-omics diagnostics, which promise to predict disease before appearance of symptoms with increasing confidence. In addition, an entirely new area of ubiquitous wearables with continuous health monitoring and artificial intelligence based real-time analysis of large datasets is promising to transform the ability to detect perturbations in our health patterns early and often. What are the implications for diagnostics products development and clinical value propositions vis-a-vis therapeutics and subsequently what are reimbursement challenges? Join this panel to learn more.